Using patient-derived tumor organoids, researchers have identified which therapies may be most effective for individual sarcoma patients.

Decitabine plus venetoclax and ponatinib appeared safe and elicited responses in a phase 2 trial of patients with advanced phase CML.

Rates of late biochemical recurrence and progression to metastasis were “strikingly low” in patients with pT2 stage disease and Gleason scores less than or equal to 3 + 4.

(HealthDay News) — An in-home cognitive behavioral therapy program improves insomnia symptoms in breast cancer survivors, according to a study published in JAMA Network Open.